ICH Q5A(R2) - Viral Safety Evaluation of Biotechnology Products

What it says

Biotechnology products derived from cell lines of human or animal origin must undergo viral safety evaluation addressing three complementary approaches: testing cell lines and raw materials for viral contamination, assessing the capacity of the manufacturing process to clear or inactivate viruses, and testing the product itself at appropriate stages for viral contamination.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• This guideline's three-pronged approach, testing, process capacity and product testing, reflects the understanding that no single control point alone is sufficient to assure viral safety for biotechnology products derived from potentially virus-susceptible cell substrates.
• Viral clearance studies, demonstrating the manufacturing process itself can inactivate or remove viral contamination even if it were present, are typically conducted using model viruses at small scale, with results extrapolated to support commercial-scale manufacturing.
• This framework connects directly to cell banking control described in EU GMP Annex 2 and the broader biological product stability considerations in ICH Q5C, together forming a connected viral and biological safety framework for biotechnology products.

What inspectors look for

• Whether viral clearance study data genuinely supports the specific commercial-scale manufacturing process, not just a substantially different small-scale model that may not represent actual process conditions.
• Whether cell line and raw material viral testing is current and appropriately comprehensive for the specific biological source materials used.
• Whether a manufacturing process change is assessed for potential impact on previously established viral clearance capacity before implementation.

Related regulations